Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Items 1-10 of 36
Camostat mesylate (HB3595)Description:
Serine protease inhibitor. Inhibits TMPRSS2 and partially blocks SARS-Cov2 entry in vitro.
Cyclosporin A (HB0220)Description:
Potent calcineurin inhibitor. Inhibits MPTP opening.Purity:
Anti-inflammatory synthetic glucocorticoid. Induces hMSC differentiation. Apoptosis inducer.Purity: